Risk factors for venous thrombosis

1. White RH: The epidemiology of venous thromboembolism. Circulation 2003; 107: I-4–I-8.)

2. Cushman M: Epidemiology and risk factors for venous thrombosis. Semin Hematol 2007; 44(2): 62–69.

3. Agnelli G, Prandoni P, Santamaria MG et al.: Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345:165–169.

4. http://www.bpac.org.nz/resources/bt/2011/03_thrombophilia.asp

5. Middeldorp S: Is thrombophilia testing useful? ASH Education Book 2011; 1:150–155.

6. Walker ID, Greaves M: Preston FE on behalf of the Haemostasis and Thrombosis Task Force British Committee for Standards in Hematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114: 512–528.

7. NICE guidance CG92 Venous thromboembolism – reducing the risk Issude: January 2010. http://guidance.nice.org.uk/CG92

8. Rosendaal FR: Risk Factors for venous thrombotic Disease. Thromb Haemost 1999; 82: 610–619.

9. Matýšková M, Paseka J, Vorlová Z et al.: Prevalence of factor V Leiden mutation in healthy women. In: Scharrer I, Schramm W: 29. Hämophilie - Symposion Hamburg 1998, Springer 1999, 309–311.

10. Rossi E. Za T, Ciminello A et al.: The risk of symptomatic pulmonary embolism due to proximal deep venous thrombosis differs in patients with different types of inherited thrombophilia. Thromb Haemost 2008; 15 (6): 1030–1034.

11. Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW: Risk of recurrent venous thromboembolism in patients with common thrombophilia. Arch Intern Med 2006; 166: 729–736.

12. Pomp ER, Lenselink, AM, Rosendaal, FR, Doggen CJM: Pregnancy, the postpartum period and prothrombotic defects: risk of venous thrombosis in the MEGA study. J Thromb Haemost 2008; 6: 632–637.

13. Dulíček P, Malý J, Kalousek I et al.: Výskyt venózního tromboembolizmu u žen s Leidenskou mutací v souvislosti s graviditou a šestinedělím. Čes Gynekol 2005; 70 (2): 133–138.

14. Robertson L, Wu O, Langhorne P et al.: For the TREATS study: Thrombophilia in pregnancy: a systematic review. Br J Haematol 2005; 132: 171–196.

15. Haverkate F: Familial dysfibrinogenemia and thrombophilia. Thromb Haemost 1995; 73(1): 151–61.

16. Kamphuisen PW, Eikenboom JCJ, Bertina RM: Elevated Factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731–738.

17. Kyrle PA, Minar E, Hirschlm M et al.: High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457–462.

18. Legnani C, Cosmi B, Cini M et al.: High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haemeatol 2004; 124: 504–510.

19. Ariëns RA: Elevated fibrinogen causes thrombosis. Blood 2011; 117(18): 4687–4688.

20. Hyánek J et al.: Hyperhomocysteinemia – unrecognized and neglected. Clin Biochem Metab 2009; 2: 83–92.

21. Kottke-Marchant K, Green R, Jacobsen DW et al.: High plasma homocystein: a risk factor for arterial and venous thrombosis in patients with normal coagulation profiles. Clin. Appl. Thrombosis/Hemostasis 1997; 3(4): 239–244.

22. Buliková A, Penka M: Antifosfolipidový syndrome – diagnostika a léčba. Vnitř Lék 2005; 51(7&8): 809–817.

23. Tondeur S, Boutruche S, Biron-Andréani C, Schved JF: Prevalence of the Jak2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study. Thromb Haemost 2009; 101: 787–789.

24. Ageno W, Squizzato A, Ambrosini F et al.: Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica 2002; 87:746–750.

25. Lee AYY: Thrombosis in cancer: An update on prevention, treatment, and survival benefits of anticoagulants. ASH Education Book 2010; 1: 144–149.

26. Horsted F, West J, Grainge J: Risk of venous thromboembolism in patients with cancer: A systematic review and meta-analysis. PLoS Med 2012; 9(7): http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001275

27. Anderson FA Jr, Spencer FA: Risk Factors for venous thromboembolism. Circulation 2003; 107: I-9–I-16.

28. Rosendaal FR: Venous Thrombosis: The Role of Genes, Environment, and Behavior. ASH Education Book 2005; 1: 1–12.

29. Blanco-Molina Á, Trujillo-Santos J, Tirado R et al.: Venous thromboembolism in women using hormonal contraceptives. Findings from the RIETE Registry. Thromb Haemost 2009; 15 (3): 478–482.

30. van Vlijmen EF, Brouwer JL, Veeger NJ et al.: Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 2007; 167: 282–289.

31. Jick H, Slone D, Westerholm B et al.: Venous thromboembolic disease and AB0 blood group type. A cooperative study. Lancet 1969; 1: 539–542.

32. Matýšková M, Zavřelová J, Pejchalová A et al.: Krevní skupiny AB0 a faktor V Leiden. Čas lék čes 2002; 141 (5): 146–151.

33. Abdollahi M, Cushman M, Rosendaal FR: Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493–498.

34. Oger E, Lacut K, Le Gal G: Hyperhomocysteinemia and low B vitamin levels are independently associated with venous thromboembolism: results from the EDITH study: a hospital-based case–control study. J Thromb Haemost 2006; 4: 793–799.

35. Hron G, Lombardi R, Eichinger S et al.: Low vitamin B6 levels and the risk of recurrent venous thromboembolism. Haematologica 2007; 92(9): 1250–1253.

36. Zakai AA, Wright J, Cushman M: Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost 2004; 2:2156–2161.

37. White RH, Zhou H, Gage BF: Effect of age on the incidence of venous thromboembolism after major surgery. J Thromb Haemost 2004; 2: 1327–1333.

38. Cannegieter SC, Doggen CJM, van Houwelingen HC, Rosen-daal FR: Travel-related venous thrombosis: results from a large population-based case control study (MEGA Study). PLoS Med 2006; 3. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.0030307

39. Steffen LM: Greater fish, fruit, and vegetable Intakes are related to lower Incidence of venous thromboembolism. The longitudinal investigation of thromboembolism etiology. Circulation 2007; 115: 188–195.

40. Baglin T, Gray E, Greaves M et al.: Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149: 209–220.

41. Dalen JE: Should patients with venous thromboembolism be screened for thrombophilia? Am J Med 2008; 121: 458-463.

42. Coppens M, Reijnders JH, Middeldorp S et al.: Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis.J Thromb Haemost 2008; 6: 1474–1477.

43. Cosmi B: Value of D-dimer testing to decide duration of anticoagulation after deep vein thrombosis: yes. J Thromb Haemost 2006; 4: 2527–2529.

44. Bruinstroop E, Klok FA, van de Ree MA et al.: Elevated D-dimer levels predict recurrence in patients with idiopathic venous thromboembolism: a meta-analysis. J Thromb Haemost 2009; 7:611–618.

45. Lijfering WM, Brouwer JLP, Veeger NJGM et al.: Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314–5322.

46. Anard-Michelot H, Siguret V, Gouin-Thibault I et al.: Screening for thrombophilic abnormalities in very elderly patients. Ann Biol Clin (Paris) 2010; 68 (6): 643–648.

47. Middeldorp S: Evidence-based approach to thrombophilia testing.J Thromb Thrombolysis 2011; 31: 275–281.